HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
HALOZYME THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$122.50+0.66 (+0.54%)
Close on Oct 19, 2026
- Market cap
- $14.85B
- P/E (TTM)
- 36.1
- Dividend yield
- –
Halozyme Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Halozyme Therapeutics | Industry median |
|---|---|---|
| Market Cap | $13.90B | $166.30M |
| Enterprise Value | $15.89B | $88.19M |
| PE Ratio | 36.14 | 20.44 |
| PS Ratio | 8.36 | 3.65 |
| PB Ratio | 96.86 | 2.03 |
| P/FCF Ratio | 17.25 | 17.44 |
| P/OCF Ratio | 16.98 | 12.98 |
Enterprise value
| Measure | Halozyme Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 9.55 | 2.51 |
| EV / EBITDA | 25.96 | 14.65 |
| EV / EBIT | 26.60 | 19.00 |
| EV / FCF | 19.71 | 20.86 |
Income (trailing twelve months)
| Measure | Halozyme Therapeutics | Industry median |
|---|---|---|
| Revenue | $1.66B | $58.34M |
| Gross Profit | $1.37B | $105.94M |
| Operating Income | $597.20M | -$21.40M |
| Pretax Income | $583.34M | -$14.34M |
| Net Income | $413.60M | -$22.46M |
| EBITDA | $611.93M | -$16.91M |
| EPS (Diluted) | $3.39 | -$0.83 |
Margins
| Measure | Halozyme Therapeutics | Industry median |
|---|---|---|
| Gross Margin | 82.4% | 52.9% |
| Operating Margin | 35.9% | -44.0% |
| Pretax Margin | 35.1% | -13.3% |
| Profit Margin | 24.9% | -40.2% |
| EBITDA Margin | 36.8% | -30.2% |
| FCF Margin | 48.5% | -9.27% |
Returns
| Measure | Halozyme Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | 173.7% | -53.2% |
| Return on Assets (ROA) | 17.9% | -40.9% |
| Return on Invested Capital (ROIC) | 21.7% | -32.4% |
| Return on Capital Employed (ROCE) | 26.7% | -38.1% |
Growth
| Measure | Halozyme Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 41.2% | 5.96% |
| Net Income Growth (YoY) | -25.8% | -35.2% |
| EPS Growth (YoY) | -22.4% | -26.2% |
| FCF Growth (YoY) | 49.1% | 2.34% |
| Revenue Growth (3Y CAGR) | 28.4% | 2.25% |
| Revenue Growth (5Y CAGR) | 39.2% | 6.48% |
| EPS Growth (3Y CAGR) | 21.1% | -0.17% |
| EPS Growth (5Y CAGR) | 23.0% | 3.77% |
Balance sheet
| Measure | Halozyme Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $163.14M | $61.43M |
| Total Debt | $2.15B | $118.52M |
| Net Cash (Debt) | -$1.98B | $15.35M |
| Net Cash Per Share | -$17.48 | $0.66 |
| Equity (Book Value) | $143.54M | $49.09M |
| Book Value Per Share | $1.26 | $1.37 |
| Tangible Book Value | -$1.36B | $23.52M |
| Working Capital | $588.59M | $76.81M |
Financial position
| Measure | Halozyme Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 2.71 | 3.34 |
| Quick Ratio | 1.79 | 2.44 |
| Debt / Equity | 14.95 | 0.52 |
| Debt / EBITDA | 3.51 | 3.44 |
| Debt / FCF | 2.66 | 4.89 |
| Net Debt / EBITDA | 3.24 | 2.36 |
| Interest Coverage | 29.41 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Halozyme Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | $818.60M | -$12.35M |
| Capital Expenditures | -$12.37M | -$1.08M |
| Free Cash Flow | $806.22M | -$20.22M |
| FCF Per Share | $7.10 | -$0.42 |
Efficiency
| Measure | Halozyme Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.72 | 0.39 |
| Inventory Turnover | 1.84 | 2.70 |
| Revenue Per Employee | $3.93M | $404.87K |
| Profits Per Employee | $977.77K | -$703.34K |
| Employee Count | 423 | 74 |
Dividends and yields
| Measure | Halozyme Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | 2.97% | -23.3% |
| FCF Yield | 5.80% | -8.72% |
Shares
| Measure | Halozyme Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 113,498,000 | 58,127,000 |
| Shares Change (YoY) | -4.19% | 10.9% |
| Shares Change (QoQ) | -3.78% | 0.54% |
| Float | 112,028,000 | 49,136,700 |
| Shares Held by Insiders | 1.30% | 11.6% |
| Shares Held by Institutions | 109.5% | 59.4% |
Taxes
| Measure | Halozyme Therapeutics | Industry median |
|---|---|---|
| Income Tax | $169.74M | $79.87K |
| Effective Tax Rate | 29.1% | 20.6% |
Scores
| Measure | Halozyme Therapeutics | Industry median |
|---|---|---|
| Graham Number | $9.82 | $18.73 |
| Graham Upside | -92.0% | -45.1% |
| Altman Z-Score | 5.19 | -0.22 |
| Piotroski F-Score | 5 | 4 |
| Beneish M-Score | -2.56 | -2.62 |
Calculated by StockData from Halozyme Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.